4.8 Review

Thyroid cancer

期刊

LANCET
卷 388, 期 10061, 页码 2783-2795

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(16)30172-6

关键词

-

资金

  1. Roche Genentech
  2. Eisai
  3. Exelixis
  4. AstraZeneca
  5. Bayer

向作者/读者索取更多资源

Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment ( surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer-medullary and anaplastic-are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据